For some multiple myeloma patients, Carvykti cut risk of death by 45%
Johnson & Johnson and Legend Biotech’s CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of care at almost three …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
